BioNTech Turbocharges COVID-19 Vaccine Development
The development of a vaccine to prevent COVID-19 infection could progress much faster than expected. On Monday, BioNTech SE (NASDAQ: BNTX) shared more details regarding BNT162, a potential mRNA-based vaccine the German drugmaker has working on in partnership with Pfizer (NYSE: PFE), the University of Pennsylvania, and the Bill and Melinda Gates Foundation.
On Monday, BioNTech announced a new collaboration with Fosun Pharma to develop BNT162 in China. The company formerly known as Shanghai Fosun Pharmaceutical Group will bring its clinical development capabilities in China to the rest of the team working on the BNT162 program called Project Lightspeed.
Image source: Getty Images.
Source Fool.com
